International audiencePlant-based transient expression is potentially the most rapid and cost-efficient system for the production of recombinant pharmaceutical proteins, but safety concerns associated with plant-specific N-glycosylation have hampered its adoption as a commercial production system. In this article, we describe an approach based on the simultaneous transient co-expression of an antibody, a suppressor of silencing and a chimaeric human β 1,4-galactosyltransferase targeted for optimal activity to the early secretory pathway in agroinfiltrated Nicotiana benthamiana leaves. This strategy allows fast and high-yield production of antibodies with human-like N-glycans and, more generally, provides solutions to many critical problems ...
Molecular pharming in plants offers exciting possibilities to address global access to modern biolog...
[EN] The production of therapeutic antibodies to combat pathogens and treat diseases, such as cance...
Antibodies represent a large proportion of therapeutic drugs currently in development. In most cases...
While plant-based transient expression systems have demonstrated their potency to rapidly express ec...
Nicotiana tabacum BY-2 suspension cells have several advantages that make them suitable for the prod...
Fc-glycosylation of monoclonal antibodies (mAbs) has profound implications on the Fc-mediated effect...
Transient recombinant protein production is a promising alternative to stable transgenic systems, pa...
N-glycosylation profoundly affects the biological stability and function of therapeutic proteins, wh...
Fc-glycosylation of monoclonal antibodies (mAbs) has profound implications on the Fc-mediated effect...
Mestrado em Engenharia Agronómica - Instituto Superior de AgronomiaGlycoproteins are a major part of...
Plants are gaining increasingly acceptance as a production platform for recombinant proteins. One re...
Plant suspension cells, especially Nicotiana tabacum Bright Yellow 2 (BY- 2), are promising hosts fo...
Abstract Background Expression of economically relevant proteins in alternative expression platforms...
The plant-based production of biopharmaceuticals has attracted interest because plants, compared to ...
Plant-specific N-glycosylation can represent an important limitation for the use of recombinant glyc...
Molecular pharming in plants offers exciting possibilities to address global access to modern biolog...
[EN] The production of therapeutic antibodies to combat pathogens and treat diseases, such as cance...
Antibodies represent a large proportion of therapeutic drugs currently in development. In most cases...
While plant-based transient expression systems have demonstrated their potency to rapidly express ec...
Nicotiana tabacum BY-2 suspension cells have several advantages that make them suitable for the prod...
Fc-glycosylation of monoclonal antibodies (mAbs) has profound implications on the Fc-mediated effect...
Transient recombinant protein production is a promising alternative to stable transgenic systems, pa...
N-glycosylation profoundly affects the biological stability and function of therapeutic proteins, wh...
Fc-glycosylation of monoclonal antibodies (mAbs) has profound implications on the Fc-mediated effect...
Mestrado em Engenharia Agronómica - Instituto Superior de AgronomiaGlycoproteins are a major part of...
Plants are gaining increasingly acceptance as a production platform for recombinant proteins. One re...
Plant suspension cells, especially Nicotiana tabacum Bright Yellow 2 (BY- 2), are promising hosts fo...
Abstract Background Expression of economically relevant proteins in alternative expression platforms...
The plant-based production of biopharmaceuticals has attracted interest because plants, compared to ...
Plant-specific N-glycosylation can represent an important limitation for the use of recombinant glyc...
Molecular pharming in plants offers exciting possibilities to address global access to modern biolog...
[EN] The production of therapeutic antibodies to combat pathogens and treat diseases, such as cance...
Antibodies represent a large proportion of therapeutic drugs currently in development. In most cases...